BEIJING, China, June 15 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK) http://www.htdsmedical.com is pleased to announce that its Mellow Hope Bio Chem China division has signed an agreement with Yunnan Walvax Biotech Co., Ltd on the issue of Haemophilus influenza type "B" conjugate vaccine.
Under the terms of the agreement Mellow Hope will be fully authorized to do the International marketing of Haemophilus influenza type "B" conjugate vaccine in the global market.
HTDS intends to begin the registration process in Chile, India, Indonesia, Egypt, and Russia, commencing in June 2009 with the brand name "MEVAC-Hib".
Yunnan Walvax Biotech Co., Ltd is the second biggest manufacturer of Haemophilus influenza type b conjugate vaccine in China.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved